1194459-28-3

Basic information

• Product Name: 6-Bromo-7-hydroxy-3,4-dihydro-1H-quinolin-2-one
• Synonyms: 6-Bromo-7-hydroxy-3,4-dihydro-1H-quinolin-2-one;6-Bromo-3,4-dihydro-7-hydroxyquinolin-2(1H)-one;6-Bromo-7-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline;6-bromo-7-hydroxy-3,4-dihydroquinolin-2(1H)-one
• CAS NO: 1194459-28-3
• Molecular Formula: C₉H₈BrNO₂
• Molecular Weight: 242.06932
• Mol File: 1194459-28-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-Bromo-7-hydroxy-3,4-dihydro-1H-quinolin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Bromo-7-hydroxy-3,4-dihydro-1H-quinolin-2-one(1194459-28-3)
• EPA Substance Registry System: 6-Bromo-7-hydroxy-3,4-dihydro-1H-quinolin-2-one(1194459-28-3)

Safety Data

• Hazardous Substances Data: 1194459-28-3(Hazardous Substances Data)

Upstream product

• 22246-18-0 7-hydroxy-3,4-dihydro-2-(1H)-quinolinone 
• 21261-76-7 N-(3-methoxyphenyl)-3-chloropropionamide 
• 536-90-3 m-Anisidine 

Downstream Products

• 1392223-84-5 6-bromo-7-ethoxy-1-methyl-3,4-dihydro-1H-quinolin-2-one 
• 1392223-86-7 7-benzyloxy-6-bromo-1-methyl-3,4-dihydro-1H-quinolin-2-one 
• 1392223-77-6 7-benzyloxy-6-(pyridin-3-yl)-3,4-dihydro-1H-quinolin-2-one 
• 1392223-78-7 7-benzyloxy-1-methyl-6-(pyridin-3-yl)-3,4-dihydro-1H-quinolin-2-one 
• 1224927-77-8 6-bromo-7-methoxy-3,4-dihydroquinolin-2(1H)-one 
• 1392223-87-8 6-bromo-7-ethoxy-3,4-dihydro-1H-quinolin-2-one 
• 1392223-89-0 7-benzyloxy-6-bromo-3,4-dihydro-1H-quinolin-2-one 
• 1392223-83-4 6-bromo-7-methoxy-1-methyl-3,4-dihydro-1H-quinolin-2-one 

Relevant articles and documents

Design of a Chemical Probe for the Bromodomain and Plant Homeodomain Finger-Containing (BRPF) Family of Proteins

The bromodomain and plant homeodomain finger-containing (BRPF) family are scaffolding proteins important for the recruitment of histone acetyltransferases of the MYST family to chromatin. Here, we describe NI-57 (16) as new pan-BRPF chemical probe of the bromodomain (BRD) of the BRPFs. Inhibitor 16 preferentially bound the BRD of BRPF1 and BRPF2 over BRPF3, whereas binding to BRD9 was weaker. Compound 16 has excellent selectivity over nonclass IV BRD proteins. Target engagement of BRPF1B and BRPF2 with 16 was demonstrated in nanoBRET and FRAP assays. The binding of 16 to BRPF1B was rationalized through an X-ray cocrystal structure determination, which showed a flipped binding orientation when compared to previous structures. We report studies that show 16 has functional activity in cellular assays by modulation of the phenotype at low micromolar concentrations in both cancer and inflammatory models. Pharmacokinetic data for 16 was generated in mouse with single dose administration showing favorable oral bioavailability.

BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS

The present disclosure provides bicyclic heterocyclic derivatives of formula (I), which may be therapeutically useful, more particularly as bromodomain inhibitors; (I), in which R1, R2, R3, R4, L1, L2, Cy1, Cy2, X, n, and dotted line have the same meaning given in the specification, and pharmaceutically acceptable salts or pharmaceutically acceptable stereoisomers thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use in diseases or disorders associated as bromodomain inhibitors. The present disclosure also provides preparation of compounds and pharmaceutical formulations comprising at least one of bicyclic heterocyclic derivatives of formula (I), together with a pharmaceutically acceptable carrier, diluent, or excipient.

1,4-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND THEIR USE FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS

The present invention provides a compound of formula IA or a pharmaceutically acceptable salt thereof; 5 (IA) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS

The present invention provides bicyclic heterocyclic derivatives of formula (I), which may be therapeutically useful, more particularly as bromodomain inhibitors; (I), in which R1, R2, R3, R4, L1, L2, Cy1, Cy2, X, n and dotted line are have the same meaning given in the specification, and pharmaceutically acceptable salts or pharmaceutically acceptable stereoisomers thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder associated as bromodomain inhibitors. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of bicyclic heterocyclic derivatives of formula (I), together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

Selective dual inhibitors of CYP19 and CYP11B2: Targeting cardiovascular diseases hiding in the shadow of breast cancer

Postmenopausal women are at high risk for cardiovascular diseases because of the estrogen deficiency. As for postmenopausal breast cancer patients, this risk is even higher due to inhibition of estrogens biosyntheses in peripheral tissue by the aromatase (CYP19) inhibitors applied. Because estrogen deficiency results in significantly elevated aldosterone levels, which are a major cause of cardiovascular diseases, dual inhibition of CYP19 and CYP11B2 (aldosterone synthase) is a promising treatment for breast cancer and the coinstantaneous cardiovascular diseases. By combination of important structural features of known CYP19 and CYP11B2 inhibitors, we succeeded in obtaining compounds 3 and 5 as selective dual inhibitors with IC50 values around 50 and 20 nM toward CYP19 and CYP11B2, respectively. These compounds showed also good selectivity toward CYP11B1 (selectivity factors (IC50 CYP11B1/IC 50 CYP11B2) around 50) and CYP17 (no inhibition).

Inhibitors of the Human Aldosterone Sythase CYP11B2

The invention provides compounds of the general formula (I) which are inhibitors of the human aldosterone synthase, and also pharmaceutical compositions containing these compounds, and a method of treating of hyperaldosteronism and/or disorders or diseases that are mediated by 11β-hydroxylase (CYP11B1) with these compounds.